AIV Logo AIV Assistant

Loading...

Logo Apellis Pharmaceuticals, Inc. - APLS Open Apellis Pharmaceuticals, Inc. in new tab

19.26 USD
P/E
59.64
EPS
0.36
P/B
6.77
ROE
14.10
Beta
0.68
Target Price
36.50 USD
Apellis Pharmaceuticals, Inc. logo

Apellis Pharmaceuticals, Inc.

🧾 Earnings Recap – Q3 2025

Apellis Pharmaceuticals delivered a strong third quarter in 2025, highlighted by the FDA approval of EMPAVELI for C3 glomerulopathy, enhancing its market position with differentiated treatment options.

  • EMPAVELI's approval increases the addressable market by approximately 5,000 patients, positioning it as the only comprehensive treatment for multiple patient populations.
  • Early feedback on EMPAVELI's launch has been overwhelmingly positive, with physicians emphasizing its efficacy and ease of use via a compact auto-injector.
  • SYFOVRE continues to face slow adoption despite its proven clinical profile, prompting strategic marketing initiatives aimed at accelerating growth in the geographic atrophy market.
📅

19.2600 USD

19.260 USD

Daily: +0.00%
Key Metrics

Earnings date: Feb. 27, 2026

P/E: 59.64

EPS: 0.36

Book Value: 3.17

Price to Book: 6.77

Debt/Equity: 118.50

% Insiders: 13.643%

Growth

Revenue Growth: 1.33%

Estimates

Forward P/E: -25.56

Forward EPS: -0.84

Target Mean Price: 36.50

DCF Valuation

Tweak assumptions to recompute fair value for Apellis Pharmaceuticals, Inc. (APLS)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Logo About Apellis Pharmaceuticals, Inc. - (APLS)

Country: United States

Sector: Health Care

Website: http://www.apellis.com

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, hematopoietic stem cell transplantation-associated thrombotic microangiopathy, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Exchange Ticker
FRA (Germany) 1JK.F
NMS (United States) APLS

Dividends

Historical Split Corporate Actions

Trades
My Trades
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion